GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Forward Dividend Yield %
Switch to:

Biogen (BUE:BIIB) Forward Dividend Yield %

: 0.00% (As of Today)
View and export this data going back to 2019. Start your Free Trial

As of today (2023-06-01), the Forward Annual Dividend Yield of Biogen is 0.00%.

As of today (2023-06-01), the Trailing Annual Dividend Yield of Biogen is 0.00%.

BUE:BIIB's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Forward Dividend Yield % only.

Biogen's Dividends per Share for the three months ended in Mar. 2023 was ARS0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Forward Dividend Yield % Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Biogen's Forward Dividend Yield % falls in comparison to its industry or sector. The grey bar indicates the Forward Dividend Yield %'s extreme value range as defined by GuruFocus.



Biogen Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Biogen  (BUE:BIIB) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Biogen Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Biogen's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines